Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults.

@article{Milji2006ChangesIP,
  title={Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults.},
  author={Dragana Milji{\'c} and Predrag S Milji{\'c} and Mirjana Doknic and Sandra Pekic and Marina Djurovic and Milica {\vC}olovi{\'c} and V. P. Popovi{\'c}},
  journal={Hormones},
  year={2006},
  volume={5 3},
  pages={
          187-91
        }
}
BACKGROUND In rodents, Growth Hormone (GH) has been shown to stimulate coagulation parameters, including Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT) and vitamin K dependent coagulation factors. However, there are no reports on the influence of GH replacement therapy on global coagulation tests in Growth Hormone Deficiency (GHD). OBJECTIVE The aim of this study was to investigate the effects of GH administration on basic coagulation parameters: PT, aPTT and fibrinogen… 

Tables from this paper

Effect of GH Treatment on Coagulation Parameters in Children with Growth Hormone Deficiency
TLDR
GH replacement therapy led to a significant increase in PT and AT levels and significant decrease in PAI-1 levels in GHD children, suggesting a beneficial effect of GH treatment against the possible risk of future atherothrombosis.
Evaluation of coagulation and fibrinolytic parameters in adult onset GH deficiency and the effects of GH replacement therapy: a placebo controlled study.
  • I. Cakır, F. Tanrıverdi, F. Keleştimur
  • Medicine, Biology
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2012
Prothrombin time, activated thromboplastin time, fibrinogen, and D-dimer levels, and von Willebrand activity of patients with Sheehan's syndrome and the effect of hormone replacement therapy
TLDR
It was determined that hormone replacement treatment did not have a significant effect on coagulation parameters except the fibrinogen and d-dimer levels.
Growth hormone replacement normalizes impaired fibrinolysis: new insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency.
  • D. Miljić, P. Miljić, V. Popović
  • Medicine, Biology
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2013
Prothrombin time (PT), activated partial thromboplastin time (APTT) and international normalized ratio (INR) as predictive factors of coagulopathy in newly diagnosed hypertensive patients
TLDR
PT and APTT are basic coagulation tests which measure integrated actions of majority of coagulations factors in extrinsic and intrinsic pathways ofCoagulation cascade of blood.
Adult-onset growth hormone deficiency: causes, complications and treatment options
TLDR
Long-term prospective trials have shown that growth hormone replacement therapy results in improvements in body composition, dyslipidemia, bone mineral density, and quality of life, but the effects on endpoints such as cardiovascular morbidity and mortality and fractures are not fully proven.
Prothrombin Time Activated Partial Thromboplastin Time and Platelets Count among Hypertensive Patients Attending a Tertiary Health Institution in Yenagoa, Nigeria
TLDR
There is need for early diagnosis to avoid hemostatic complications and to aid effective management of the patients, as there were significant variations between the hypertensive and control subjects for each of the parameters.
Role of insulin-like growth factor 1 in stent thrombosis under effective dual antiplatelet therapy
  • A. Yalçın, M. Topuz, F. Uzun
  • Medicine, Biology
    Postepy w kardiologii interwencyjnej = Advances in interventional cardiology
  • 2014
TLDR
Investigating the associations between stent thrombosis under effective dual antiplatelet therapy and IGF-1 levels and other related factors such as disease severity and LV ejection fraction in patients undergoing coronary stent placement revealed that the plasma IGF- 1 levels, disease severity, were significantly higher and LVEF was lower in patients with ST.
Hemostatic abnormalities in endocrine and metabolic disorders.
TLDR
Globally, the disorders of coagulation and fibrinolysis usually range from mild to moderate, and, rarely, to severe laboratory abnormalities (for example, bleeding diathesis in overt hypothyroidism mainly due to an acquired von Willebrand's disease type 1).
...
...

References

SHOWING 1-10 OF 10 REFERENCES
Growth hormone deficiency impairs blood clotting and reduces factor VII coagulant activity in rat.
TLDR
GH is of importance for normal hemostasis in the female rat and the prothrombin time, platelet count, and factors II, VII, IX, and X were slightly increased after GH substitution but not after cortisone, thyroxine, or vitamin K treatment.
Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
TLDR
The present results suggest that GH plays a role in the regulation of fibrinolysis and changes may be a direct effect of GH itself or may be secondary to the favourable changes in body composition.
Conjugated equine oestrogens and blood clotting: a follow-up report.
TLDR
A follow-up study of blood clotting and platelet aggregation was performed on 21 women who had received long-term hormone replacement treatment with conjugated equine oestrogens, finding that there was no further increase with continual administration for 18 months, which suggested a widening spectrum of effect.
Effects of growth hormone on the factor VIII complex in patients with growth hormone deficiency.
Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women.
TLDR
It is demonstrated that men and women with GHD display marked differences in their responsiveness to GH replacement therapy, and these differences should be taken into consideration when optimizing the treatment of GHD patients.
Somatotropin and somatostatin effects on vitamin K-dependent plasma coagulation factors.
Regulation of growth hormone and somatomedin-C secretion in postmenopausal women: effect of physiological estrogen replacement.
TLDR
Estrogen therapy increased spontaneous and exercise-induced GH secretion in postmenopausal women and reduced Sm-C levels, and the mechanisms of GH elevation by estrogen may include both central effects and a negative feedback linkage to reduced plasma Sm activity.
Induction of the estrogen receptor by growth hormone and glucocorticoid substitution in primary cultures of rat hepatocytes.
TLDR
The regulatory effects of GH and DEX on the hepatic ER in this in vitro system are very similar to the effects of these hormones under in vivo conditions.
Oral contraceptives and the risk of venous thrombosis.
TLDR
In the early 1960s, shortly after the introduction of oral contraceptives, the first case reports appeared describing venous thrombosis and pulmonary emboli in women using this method of birth control, leading to the development of new oral contraceptives with a lower estrogen content.